Axon Peer In Buy Range After Flashing This Telltale Signal

WASHINGTON , Dec. 2, 2024 /PRNewswire/ -- Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry's economic performance, its impacts, and its geographic footprint. The report, " The U.S. Bioscience Economy: Driving Economic Growth and Opportunity in States and Regions ," analyzes the sector's economic impact via employment, overall output, wages/benefits, and tax revenue. Key takeaways from the report include: "America's bioscience sector is vital to addressing the world's most pressing challenges -- from pandemics and national security to preventative health and environmental sustainability. Industry leaders and researchers overcome tremendous obstacles every day to advance innovative solutions and help people lead healthier lives, and this report shows how the sector continues to enrich communities, create jobs, and grow economies across our great country," said John F. Crowley , BIO's President & CEO. "For two decades now, this report series has shown the growth and impact of the bioscience industry on the economy. In the wake of the COVID-19 pandemic and economic downturns, it is clear that the biosciences remain a key sector of the growing innovation economy," said Pete Pellerito , BIO Senior Policy Adviser for Federal and State Economic Development and Technology Transfer Initiatives. "The bioscience industry's economic footprint extends to every U.S. state and region," said Ryan Helwig , Principal and Project Director with TEConomy Partners. "That means all parts of the country play a part in the industry's breakthroughs and advancements and benefit from its economic impact." The state-by-state industry assessment is the eleventh in a biennial series, developed in partnership by TEConomy Partners and BIO , and studies the state of the U.S. bioscience industry and its associated innovation ecosystem at the national, state, and metropolitan area levels. The report includes individual fact sheets for all 50 states, the District of Columbia , and Puerto Rico , which can be found alongside the full report and map at www.bio.org/jobs . About BIO BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products. BIO also produces the BIO International Convention , the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. About Council of State Bioscience Associations The Council of State Bioscience Associations (CSBA) is a coalition of independent state and territory based non-profit trade associations, each of which advocates for public policies that support responsible development and delivery of innovative life-sustaining and life-saving biotechnology solutions. Convened by the Biotechnology Innovation Organization (BIO), CSBA's collective voice represents the true grassroots network of innovators, researchers, manufacturers and accelerators across the country. About TEConomy TEConomy Partners, LLC is a global leader in research, analysis and strategy for innovation-driven economic development. Today we're helping nations, states, regions, universities and industries blueprint their future and translate knowledge into prosperity. The principals of TEConomy Partners include the authors of the prior Battelle/BIO State Bioscience Development reports, published since 2004. For further information, please visit www.teconomypartners.com . CONTACT- Vicky Stinson | vstinson@bio.org View original content to download multimedia: https://www.prnewswire.com/news-releases/new-report-finds-bioscience-sector-generates-over-3-trillion-for-us-economy-302320044.html SOURCE Biotechnology Innovation Organization (BIO)

Ultrahigh pressure generation in Walker-type press could help with understanding Earth's interiorAP Business SummaryBrief at 1:24 p.m. ESTIf you have room in your portfolio for some new ASX 200 shares, then it could be worth checking out the two listed below. That's because they have recently been named as buys by analysts and tipped to have very bright futures. Here's what they are saying: ( ) The first ASX 200 growth share that analysts are tipping as a buy is Megaport. It offers scalable bandwidth for public and private cloud connections, metro ethernet, data centre backhaul, and internet exchange services. The company's software layer provides users with a clever and easy way to create and manage network connections. Through the Megaport network, businesses can deploy private point-to-point connectivity between any of the locations on Megaport's global network infrastructure. This leaves the company extremely well-positioned to benefit from the structural shift to the cloud and the artificial intelligence (AI). In fact, Goldman Sachs believes Megaport has an enormous growth potential. It has previously stated that it estimates that the company's "opportunity for further growth is immense [with] GSe A$129bn p.a. spent on fixed enterprise networking across MP1 geographies." It adds: While acknowledging mixed near-term execution around the partner channel and the new MVE product, we are Buy rated on the name as we remain confident MP1 has a clear product advantage vs. peers and a decade-long runway for robust growth. Despite the soft operational trends in recent periods, we expect still robust top-line growth, with the increased focus on profitable growth supporting an attractive earnings profile over FY25-26. The broker has a buy rating and $10.40 price target on its shares. ( ) Another ASX 200 growth share that has been named as a buy is WiseTech Global. It is the logistics solutions company behind the popular CargoWise One platform. The company notes that CargoWise One is regarded as the logistics industry's most advanced enterprise-class management system, with a deeply feature-rich set of vertical and horizontal, whole-of-enterprise capabilities that provide comprehensive functionality for logistics execution needs across the supply chain. Given the quality of its platform, the company boasts incredible industry adoption rates, high recurring revenue, and ultra low churn rates. This has been underpinning strong earnings and revenue growth for some time and Bell Potter believes more of the same is coming. It said: At its recent AGM, WTC downgraded its FY25 guidance by up to around 10% at revenue and 15% at EBITDA, principally due to the delay in the release of one of the company's new products – Container Transport Optimisation – due to "distractions flowing from the recent media attention and the organisational changes that have subsequently been implemented." The release is now expected to occur in 2HFY25 rather than 1HFY25, and we note that the releases of the company's other new products – ComplianceWise and CargoWise Next – are on track. In our view, WTC appears oversold at current levels and as one of the best growth names on the market, the recent downgrade presents a buying opportunity. Bell Potter has a buy rating and $140.00 price target on its shares.